Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank König

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Psychiatrische Praxis|September 12, 2002
[Improvement of tardive dyskinesia after treatment with olanzapine]Steve Truöl, Christoph Von Hippel, Jan Raape, et al.
Toxicology|July 25, 2021
Phototoxic versus photoprotective effects of tattoo pigments in reconstructed human skin models: In vitro phototoxicity testing of tattoo pigments: 3D versus 2DHenrik Hering, Christian Zoschke, Frank König, et al.
Aktuelle Urologie|September 20, 2017
[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]Frank Christoph, Frank König, Stefan Lebentrau, et al.
World Journal of Urology|December 6, 2017
RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer diseaseFrank Christoph, Frank König, Steffen Lebentrau, et al.
Anticancer Research|March 14, 2007
Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray studyFrank König, Gisbert Krekeler, Johannes F Hönig, et al.
BMC Urology|December 18, 2015
Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registryGötz Geiges, Thomas Harms, Gerald Rodemer, et al.
World Journal of Urology|August 14, 2016
Nephron sparing surgery for renal cell carcinoma up to 7 cm in the context of guideline development: a contribution of healthcare researchSteffen Lebentrau, Sven Rauter, Daniel Baumunk, et al.
Aktuelle Urologie|May 24, 2023
[The cancer registry notification seen from the perspective of the German Society of Uro-Oncologists (d-uo)]Christian Doehn, Manfred Johannsen, Rolf Eichenauer, et al.
Aktuelle Urologie|May 24, 2023
[Real-world data on prostate cancer: the VERSUS trial by d-uo]Jörg Klier, Frank König, Manfred Johannsen, et al.
Aktuelle Urologie|March 4, 2026
[Current Data from the National Registry for Prostate Cancer (ProNAT) by d-uo]Frank König, Manfred Johannsen, Jörg Klier, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Psychiatrische Praxis|September 12, 2002
[Improvement of tardive dyskinesia after treatment with olanzapine]Steve Truöl, Christoph Von Hippel, Jan Raape, et al.
Toxicology|July 25, 2021
Phototoxic versus photoprotective effects of tattoo pigments in reconstructed human skin models: In vitro phototoxicity testing of tattoo pigments: 3D versus 2DHenrik Hering, Christian Zoschke, Frank König, et al.
Aktuelle Urologie|September 20, 2017
[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]Frank Christoph, Frank König, Stefan Lebentrau, et al.
World Journal of Urology|December 6, 2017
RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer diseaseFrank Christoph, Frank König, Steffen Lebentrau, et al.
Anticancer Research|March 14, 2007
Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray studyFrank König, Gisbert Krekeler, Johannes F Hönig, et al.
BMC Urology|December 18, 2015
Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registryGötz Geiges, Thomas Harms, Gerald Rodemer, et al.
World Journal of Urology|August 14, 2016
Nephron sparing surgery for renal cell carcinoma up to 7 cm in the context of guideline development: a contribution of healthcare researchSteffen Lebentrau, Sven Rauter, Daniel Baumunk, et al.
Aktuelle Urologie|May 24, 2023
[The cancer registry notification seen from the perspective of the German Society of Uro-Oncologists (d-uo)]Christian Doehn, Manfred Johannsen, Rolf Eichenauer, et al.
Aktuelle Urologie|May 24, 2023
[Real-world data on prostate cancer: the VERSUS trial by d-uo]Jörg Klier, Frank König, Manfred Johannsen, et al.
Aktuelle Urologie|March 4, 2026
[Current Data from the National Registry for Prostate Cancer (ProNAT) by d-uo]Frank König, Manfred Johannsen, Jörg Klier, et al.
Pageof 3